What biomarker tests are recommended for Liver Cancer

Biomarker Tests for Liver Cancer (HCC)

I'm glad you're asking about this—understanding the biomarkers used to detect and monitor liver cancer is really important for your care.

Primary Biomarker: Alpha-Fetoprotein (AFP)

AFP is the most widely used biomarker for hepatocellular carcinoma (HCC). Here's what you need to know:

How AFP Works:

AFP is a protein produced by liver cancer cells. Your doctor measures it in your blood to help detect HCC and monitor how well treatment is working.

Important Context About AFP:

According to NCCN Guidelines, AFP has some important limitations:

• Only 18% of HCC patients have very high AFP levels (>400 ng/mL)
• 46% of patients with HCC have normal AFP levels (<20 ng/mL)
• AFP can be elevated in non-cancer conditions like chronic hepatitis B or C, pregnancy, and other cancers

This means: A normal AFP doesn't rule out liver cancer, and an elevated AFP doesn't automatically mean you have cancer. That's why imaging is so important.

AFP as a Screening Tool:

The NCCN Guidelines recommend ultrasound combined with AFP testing every 6 months for people at risk for HCC. Research shows:

• AFP alone detects 69% of cases
• Ultrasound alone detects 84% of cases
• Combined AFP + ultrasound detects 92% of cases

Monitoring AFP Trends:

An interesting finding: A progressive elevation rate of ≥7 ng/mL per month may be more useful as a diagnostic tool than using a single fixed cutoff value like 200 ng/mL.

---

Additional Biomarkers Being Studied

According to NCCN Guidelines, researchers are evaluating other biomarkers that may improve detection:

Des-Gamma-Carboxy Prothrombin (DCP/PIVKA-II)

• Another protein produced by HCC cells
• May be useful when combined with AFP
• Research shows AFP + DCP together is superior to either biomarker alone

AFP-L3 (Lens Culinaris Agglutinin-Reactive AFP)

• A specific form of AFP
• Being studied as a complementary test
• Not considered optimal on its own

The GALAD Model

This is a newer scoring system that combines:

• Gender
• Age
• AFP-L3
• AFP
• Des-carboxy-prothrombin (DCP)

NCCN Guidelines note that in validation studies, the GALAD model identified HCC in patients with chronic liver disease with high accuracy. An enhanced version called GALADUS (which adds ultrasound) showed even better performance.

Multitarget Blood Tests

Newer blood tests that measure multiple markers simultaneously are being developed and show promise for early detection, though NCCN Guidelines note there is no demonstrated benefit over other established tests yet.

---

How These Tests Are Used in Clinical Practice

NCCN Guidelines explain that biomarkers are used in three main ways:

1. Screening (finding cancer early in at-risk patients)
2. Diagnosis (confirming HCC when a liver mass is found)
3. Monitoring (tracking treatment response and detecting recurrence)

Important: Imaging is More Definitive

According to NCCN Guidelines: "The Panel considers an imaging finding of classic enhancement to be more definitive in the diagnostic setting compared to AFP alone."

This means your doctor will likely use imaging (CT or MRI) along with biomarkers to make a diagnosis.

---

Questions to Ask Your Oncology Team

1. What is my baseline AFP level, and what does it mean for my specific situation?

2. Will you be monitoring my AFP regularly, and what changes would trigger additional testing?

3. Are you using any additional biomarkers (like DCP, AFP-L3, or GALAD score) in my care?

4. How often should I have biomarker testing, and what's the schedule?

5. If my AFP is normal, does that mean I don't have liver cancer, or will you rely more on imaging?

6. Are there any newer biomarker tests you recommend for my specific type of HCC?

---

Key Takeaway

Biomarkers like AFP are valuable tools, but they work best in combination with imaging and your clinical picture. No single test tells the whole story. Your oncologist will interpret these results together with your imaging, liver function tests, and medical history to guide your treatment decisions.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.